Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Alaunos Therapeutics, Inc.

NASDAQ: TCRT · Life Sciences · 6 alerts · CIK 1107421

Share price
$1.60Close, Nov 16
Market cap
$4.06M
Shares outstanding
2.54MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Alaunos Therapeutics, Inc. filings on SEC EDGAR ↗

4:42 PM ET 10-Q
Financial Results

Alaunos Therapeutics Q3 2026 Results: Net Loss of $772K, Loss Narrows

Alaunos Therapeutics reported a net loss of $2.7 million for the nine months ended September 30, 2026, as it transitioned from TCR therapies to pulmonary arterial hypertension treatments. The company's cash position decreased to $615,000, and it recently acquired Velaris Therapeutics in October 2026 to bolster its pipeline.

Key figure
Net loss $772K
4:31 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Alaunos Therapeutics Nasdaq/NYSE Compliance Notice

Alaunos Therapeutics has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2,500,000 following a private placement financing. As a result, the previously scheduled delisting hearing has been cancelled and the company's common stock will continue to trade on The Nasdaq Capital Market.

Counterparty
Nasdaq
4:31 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Alaunos Therapeutics Nasdaq/NYSE Compliance Notice

Alaunos Therapeutics received a delisting notice from Nasdaq on October 5, 2026, due to continued non-compliance with the $2.5 million minimum stockholders' equity requirement. The company has requested a hearing before the Nasdaq Hearings Panel, currently scheduled for November 10, 2026, which has stayed any delisting action pending the outcome.

Counterparty
The Nasdaq Stock Market LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.